To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC78109 | [Ru(dpp)(bpy)(mtmp)](PF6)2 |
[Ru(dpp)(bpy)(mtmp)](PF6)2 (Compound 5) is a trisheteroleptic ruthenium complex. [Ru(dpp)(bpy)(mtmp)](PF6)2 has a light-activated anticancer activity. [Ru(dpp)(bpy)(mtmp)](PF6)2 can selectively cleave off upon green light irradiation, thereby releasing a phototoxic ruthenium-based photoproduct that binds to nuclear DNA, induces DNA damage and apoptosis in cancer cells. [Ru(dpp)(bpy)(mtmp)](PF6)2 can be used for phototherapy of cancers like conjunctival melanoma research.
More description
|
|
| DC78108 | JNJ-17166864 |
JNJ-17166864 is a highly selective CCR2 antagonist. JNJ-17166864 has low oral bioavailability. JNJ-17166864 can significantly reduce the area of alveolar bone loss in a mouse model of periodontitis induced by Porphyromonas gingivalis infection. JNJ-17166864 can be used in the research of inflammatory diseases such as allergic rhinitis and periodontitis.
More description
|
|
| DC78107 | SM (d18:1/15:0) |
SM (d18:1/15:0) is a sphingomyelinase inhibitor. SM (d18:1/15:0) is promising for research of neurodegenerative diseases (e.g., Alzheimer's) and metabolic syndrome.
More description
|
|
| DC78106 | (S)-Edelfosine |
(S)-Edelfosine ((S)-ET-18-OCH3) is the (S)-enantiomer of Edelfosine (ET-18-OCH3). Edelfosine is a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 Death receptor.
More description
|
|
| DC78105 | SDZ-CPI 975 |
SDZ-CPI-975 is a novel, reversible, and selective CPT I inhibitor. SDZ-CPI-975 effectively inhibits fatty acid oxidation and lowers blood glucose levels.
More description
|
|
| DC78104 | AR ligand-44 TFA |
AR ligand-44 TFA is an androgen receptor ligand that can be used in the synthesis of PROTACs, such as ARD-2051.
More description
|
|
| DC78103 | AR ligand-44 |
AR ligand-44 is an androgen receptor ligand that can be used in the synthesis of PROTACs, such as ARD-2051.
More description
|
|
| DC78102 | mrt-5702D |
mrt-5702D is a molecular glue degrader targeting cereblon (CRBN). mrt-5702D forms a CRBN-MRT-5702D-G3BP2 ternary complex to activate the ubiquitin-proteasome system for G3BP2 degradation. mrt-5702D is promising for research of G3BP2-related cancers (e.g., breast cancer, lung cancer) and neurodegenerative diseases.
More description
|
|
| DC78101 | Angustilongine M |
Angustilongine M is a microtubule-targeting antitumor alkaloid (IC50=0.2 μM against HT-29 cells). Angustilongine M induces G0/G1 cell cycle arrest and mitochondrial apoptosis via tubulin polymerization promotion. Angustilongine M is promising for research of colorectal cancer and other solid tumors.
More description
|
|
| DC78100 | BAL-0019764 |
BAL-0019764 is an iron carrier monocyclic β-lactam with broad-spectrum β-lactase inhibition ability. BAL-0019764 has inhibitory activity against various Gram negative bacteria. BAL-0019764 is commonly used in the study of bacterial infections.
More description
|
|
| DC78099 | Z52/Z56 intermediate |
Z52/Z56 intermediate is a key intermediate in the synthesis of RAS inhibitors.
More description
|
|
| DC78098 | GJ19 |
GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with KD values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy.
More description
|
|
| DC78097 | BIRT2584 |
BIRT2584 is an LFA-1 inhibitor. BIRT2584 can be used for research on autoimmune diseases.
More description
|
|
| DC78096 | Tisolagiline methylsulfate |
Tisolagiline (KDS2010) methylsulfate is the selective, reversible and orally active inhibitor for MAO-B with an IC50 of 8 nM. Tisolagiline methylsulfate exhibits neuroprotective and anti-neuroinflammatory activities.
More description
|
|
| DC78095 | BMS-279700 |
BMS-279700 is an orally active Src-family kinase p56Lck inhibitor. BMS-279700 can block the production of proinflammatory cytokines (IL-2 and TNFα). BMS-279700 can inhibit T cell proliferation. BMS-279700 can be used for the researches of inflammation and immunology.
More description
|
|
| DC78094 | Topoisomerase inhibitor 6 |
Topoisomerase inhibitor 6 (Compound REDX05931) is a dual irreversible inhibitor of DNA gyrase and topoisomerase IV (MIC=0.06 μg/mL against fluoroquinolone-resistant S. aureus). Topoisomerase inhibitor 6 blocks DNA strand break-reunion, inducing lethal DNA damage. Topoisomerase inhibitor 6 is promising for research of Gram-positive bacterial infections (e.g., S. aureus, S. pneumoniae).
More description
|
|
| DC78093 | Lorotomidate |
Lorotomidate (Example 16) is a GABAA receptor agonist. Lorotomidate has anaesthetic effects (ED50: i.v., 2 mg/kg in KM mice; LD50: 46.5 mg/kg in KM mice). Lorotomidate has no inhibitory effect on the secretion of corticosteroids in animals, and thus has good safety.
More description
|
|
| DC78092 | (R)-ACE-OH |
(R)-ACE-OH is the enantiomer of (S)-ACE-OH.
More description
|
|
| DC78091 | (R)-PHA533533 |
(R)-PHA533533 is an inactive enantiomer (S)-PHA533533 (active enantiomer). (S)-PHA533533 is a CDK2 inhibitor with antitumor activity.
More description
|
|
| DC78090 | SMU-037 |
SMU-037 is an orally active and selective ROS1 inhibitor that demonstrates potent activity (IC₅₀ = 6.8 nM) and possesses the ability to penetrate the blood-brain barrier. SMU-037 shows ~25-fold selectivity over ALK, and superior sensitivity against the G2032R mutation. SMU-037 attenuates phosphorylation of ROS1 and downstream MAPK-ERK signaling pathway, leading to cell cycle arrest and apoptosis. SMU-037 effectively suppresses tumor progression in both xenograft and intracranial mouse models. SMU-037 can be used for non-small cell lung cancer (NSCLC) research.
More description
|
|
| DC78089 | A-75998 |
A-75998 is an antagonist of luteinizing hormone-releasing hormone (LHRH). A-75998 can be used in the research of diseases such as hormone-sensitive cancers and endometriosis.
More description
|
|
| DC78088 | MK-5932 |
MK-5932 is an orally active, selective, dissociated partial glucocorticoid receptor agonist. MK-5932 inhibits IL-6. MK-5932 induces lymphopenia. MK-5932 restores glucose levels to normal. MK-5932 shows anti-inflammatory effects.
More description
|
|
| DC78087 | (±)-PM 92131 |
(±)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (±)-PM 92131 has an anti-HIV-1 activity with IC50s of 45.7 and 53.8 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (±)-PM 92131 can be used for HIV infections research.
More description
|
|
| DC78086 | Soficitinib |
Soficitinib (Compound 20) is a selective inhibitor targeting tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) with an IC50 values of 0.5 nM and 1.2 nM, respectively. Soficitinib is promising for research of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis) and inflammatory diseases.
More description
|
|
| DC78085 | KC-11458 |
KC-11458 is a motilin agonist. KC-11458 can accelerate gastric emptying.
More description
|
|
| DC78084 | NKS-01 |
NKS-01 is a selective estrogen receptor modulator. NKS-01 can be used for the research of cancer, such as estrogen receptor-positive breast cancer.
More description
|
|
| DC78082 | HMR-3787 |
HMR-3787 is a 2-fluoroketolide and bactericide. HMR 3787 is bactericidal against 12 H. influenzae strains.
More description
|
|
| DC78081 | MS-153 |
MS-153 is a glutamate transporter activator that can be used as a neuroprotective agent.
More description
|
|
| DC78080 | Dazodeunetant |
Dazodeunetant (Example 56) is a nitrogen-containing fused ring derivative. Dazodeunetant is an inhibitor of neurokinin (NK). Dazodeunetant has an IC50 0f 75.99 nM against NK3R in HEK293-NK3 (IP1). Dazodeunetant can be studied in research for menopausal hot flashes.
More description
|
|
| DC78079 | Asuptegravir |
Asuptegravir (Compound 1) is an inhibitor of HIV integrase activity. Asuptegravir inhibits HIV in HEK293T cells (EC50 = 1.08 nM). Asuptegravir can be studied in anti-AIDs/HIV research.
More description
|
|